PDCD1 and neoplasm: In regard to adjuvant treatment that may directly eliminate micro-metastatic tumors upon surgical resection, the application of neoadjuvant PD-1 blockade while the primary tumor is in place may leverage a higher level of endogenous tumor antigen release in the primary tumor to further promote T-cell priming.